Financial comparisons Insmed Incorporated
Equities
INSM
US4576693075
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 148.55 USD | -0.66% |
|
-3.53% | -14.65% |
| 28/01 | Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target | MT |
| 23/01 | Roth Capital Initiates Coverage on Insmed With Buy Rating, $212 Price Target | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 36Cr | -251.24% | -241.47% | -1,601.19% | -54.47% | 0.16x | |
| 221.87Cr | 36.99% | -0.96% | 2.26% | 2.02% | 818.71x | |
| 537.62Cr | 24.08% | 29.51% | 16.78% | 12.27% | -0.97x | |
| 284.82Cr | -24.18% | -47.77% | -3.3% | -2.88% | 9.36x | |
| 255.86Cr | 17.97% | 25.37% | 11.65% | 8.43% | -0.66x | |
| 298.83Cr | 36.44% | 32.53% | 22.97% | 19.34% | -2.97x | |
| 26Cr | -13.8% | -7.18% | -9.46% | -9.11% | 18.95x | |
| 29Cr | -24.22% | -26.28% | -8.94% | -4.69% | -2.82x | |
| 216.87Cr | 24.04% | 27.88% | 23.13% | 17.7% | -1.75x | |
| 18Cr | -258.64% | -276.39% | -80.35% | - | 1.63x | |
| 83Cr | -0.2% | 11.86% | -0.5% | - | -6.61x | |
| 30Cr | 30.46% | 17.83% | 7.52% | 6.63% | -9.98x | |
| 1.85Cr | -3,191.11% | -2,902.72% | - | -52.97% | 0.77x | |
| 24Cr | -85.53% | -78.53% | -54.06% | -26.62% | -1.54x | |
| Average | 147.42Cr | -262.78% | -245.45% | -128.73% | -7.03% | 58.74x | |
| Weighted average by Cap. | 215.72Cr | -120.66% | -119.87% | -192.22% | -4.6% | 154.47x |
- Stock Market
- Equities
- INSM Stock
- Sector Insmed Incorporated
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition